Dr Johann de Bono, whose group presented the phase I data that generated so much recent interest, has been captured on video at the Prostate Cancer Foundation Scientific Retreat.

In the talk, covers the background behind the drug's development in prostate cancer, as well as explaining the data so far in patients who have failed standard docetaxel chemotherapy.

You can view the videos here and here.

There is more information on a previous post about how abiraterone works in prostate cancer.  The drug is now in phase III development and new trials in breast cancer are expected to start soon.

Reblog this post [with Zemanta]